1. PROTAC
  2. PROTAC

PROTAC

PROTACs (Proteolysis Targeting Chimeric Molecules) are heterobifunctional nanomolecules that structurally comprised of two functional motifs linked by a linker. One motif is a small molecule ligand for the target protein of interest, while the other recognizes a specific E3 ligase. By recruiting an E3 ligase to a target protein and formation of a ligase:PROTAC:target ternary complex, A PROTAC leads to polyubiquitylation and subsequent degradation of target through ubiquitin-proteasome system (UPS). PROTACs have desirable features such as the ability to target the “undruggable” proteome and overcome the accumulation of the drug targets and will be promising targeted therapeutics for cancers.

Among the hundreds of E3 ligases, VHL (von Hippel-Lindau disease tumor suppressor protein), CRBN (Cereblon), MDM2 (the mouse double minute 2 homologue) and cIAP (cellular inhibitor of apoptosis 1) are reported to target kinases (such as MEK, KRAS, CDK and Bcr/Abl), transcription factors (such as p53, STAT, RAR, ER and AR), and epigenetic readers (BET bromodomain such as BRD family) and are most widely used in the development of PROTACs. There are also some specific types of PROTACs, such as homo-PROTACs and general PROTACs for tagged fusion proteins. Homo-PROTACs intend to dimerize an E3 ligase and then induce its self-degradation, while general PROTACs for tagged fusion proteins can bind to general tags(such as HaloTag and FKBP12) and then induce the degradation of fusion proteins.

PROTAC Related Products (85):

Cat. No. Product Name Effect Purity
  • HY-100972
    ARV-771 99.82%
    ARV-771 is a potent BET degrader based on PROTAC technology with Kds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and BRD4(2), respectively[1].
  • HY-112588
    dBET6 Inhibitor 99.40%
    dBET6 is a highly potent, selective and cell-permeable degrader of BET based on PROTAC, with an IC50 of 14 nM, and has antitumor activity.
  • HY-16954
    ARV-825 99.37%
    ARV-825 is a BRD4 degrader based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively.
  • HY-107425
    MZ 1 98.87%
    MZ 1 is a PROTAC BRD4 degrader. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. Kds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively[1].
  • HY-101838
    dBET1 99.24%
    dBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC50 of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker[1].
  • HY-134582
    dCBP-1
    dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on PROTAC. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression[1].
  • HY-131911
    PROTAC IDO1 Degrader-1
    PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to CRBN E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC50=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells[1].
  • HY-111518
    JH-XI-10-02 98.18%
    JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC50 of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19[1].
  • HY-101519
    BETd-260 98.10%
    BETd-260 (ZBC 260) is a potent PROTAC BET degrader, with as low as 30 pM against BRD4 protein in RS4;11 leukemia cell line[1]. BETd-260 potently suppresses cell viability and robustly induces apoptosis in hepatocellular carcinoma (HCC) cells[2].
  • HY-129523
    PROTAC K-Ras Degrader-1 98.05%
    PROTAC K-Ras Degrader-1 (Compound 518) is potent K-Ras degrader based PROTAC, exhibits ≥70% degradation efficacy in SW1573 cells[1].
  • HY-112495
    VH032-PEG5-C6-Cl 98.10%
    VH032-PEG5-C6-Cl (HaloPROTAC 2) is a small molecule HaloPROTAC that incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1].
  • HY-111556
    BSJ-03-123 99.45%
    BSJ-03-123 is a potent and novel CDK6-selective small-molecule degrader (PROTAC).
  • HY-123921
    Gefitinib-based PROTAC 3 99.98%
    Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively[1].
  • HY-111433
    BRD4 degrader AT1 98.76%
    BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.
  • HY-114305
    A1874 98.38%
    A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation[1].
  • HY-123937
    THAL-SNS-032 99.16%
    THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN)[1].
  • HY-114312
    MD-224 Inhibitor 99.74%
    MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells, and achieves an IC50 value of 1.5 nM in inhibition of growth of RS4;11 cells. MD-224 has the potential to be a new class of anticancer agent[1].
  • HY-129602
    SD-36 99.46%
    SD-36 is a potent and efficacious PROTAC STAT3 degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of CRBN ligand Lenalidomide for E3 ubiquitin ligase[1].
  • HY-122826
    ZXH-3-26 98.39%
    ZXH-3-26 is a selective PROTAC BRD4 degrader with a DC50/5h. The DC50/5h refers to half-maximal degradation after 5 hours of treatment of ~ 5 nM[1].
  • HY-130604
    DT2216 99.92%
    DT2216 is a potent and selective BCL-XL degrader based on PROTAC technology. DT2216 causes effective degradation of BCL-XL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets[1].